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Abstract
Objective: The aim of this study was to characterize the genetic variance of somatostatin receptor 5
(SSTR5) and investigate the possible correlation of such variants with acromegaly risk and different
disease characteristics.
Design and methods: The SSTR5 gene coding region and 2000 bp upstream region was sequenced in
48 patients with acromegaly and 96 control subjects. Further, three single nucleotide poly-
morphisms (SNPs) were analyzed in the same group of acromegaly patients and in an additional group
of 475 age- and sex-matched controls.
Results: In total, 19 SNPs were identiﬁed in the SSTR5 gene locus by direct sequencing. Three SNPs
(rs34037914, rs169068, and rs642249) were signiﬁcantly associated with the presence of
acromegaly using the initial controls. The allele frequencies were signiﬁcantly (P!0.01) different
between the acromegaly patients and the additional large control group. rs34037914 and rs642249
remained signiﬁcantly associated with acromegaly after Bonferroni correction and permutation tests
(odds ratio (OR)Z3.38; 95% conﬁdence interval (CI), 1.78–6.42; PZ0.00016 and ORZ2.41; 95%
CI, 1.41–4.13; PZ0.0014 respectively). Haplotype reconstruction revealed two possible risk
haplotypes determined by rs34037914 (633T) and rs642249 (1044A) alleles. Both haplotypes
were found in signiﬁcantly higher frequency in acromegaly patients compared with controls
(P!0.001). In addition, the 663Tallele was signiﬁcantlyassociated with ayounger age of acromegaly
diagnosis (unstandardized regression coefﬁcient bZK10.4; PZ0.002), increased body mass index
(bZ4.1; PZ0.004), higher number of adenoma resection (P!0.001) and lack of observable tumor
shrinkage after somatostatin analog treatment (PZ0.014).
Conclusions: Our results demonstrate a previously undetected strong association of two SSTR5 SNPs
with acromegaly. The data also suggest a possible involvement of SSTR5 variants in decreased
suppression of GH production and increased tumor proliferation.
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Introduction
Acromegaly is a rare chronic disease mainly caused by
pituitary GH overexpressing adenomas (1). The general
characteristics of acromegaly are elevated levels of GH
and insulin-like growth factor 1 (IGF1). Disease incites
high morbidity and increased risk of mortality if it is not
properly treated (2). One of the main physiological
mediators of GH secretion and regulation of tumor
proliferation is somatostatin acting through the
somatostatin receptors (SSTRs), a family of G protein-
coupled receptors (GPCRs) including ﬁve subtypes
(SSTR1–5) (3, 4). Two of these receptor subtypes
SSTR2 and SSTR5 are found in high levels in pituitary
somatotropinomas (5), which is in contrast to other
SSTR subtypes. Accordingly, somatostatin analogs (SA)
such as octreotide and lanreotide, that have the highest
afﬁnity to SSTR2 and SSTR5, are used to repress GH
secretion in acromegaly patients (6, 7). Although the
introduction of these drugs has greatly improved
therapy for the disease, a signiﬁcant proportion of the
patients do not adequately respond to treatment
resulting in incomplete reduction in GH and IGF1 levels
(8, 9). Moreover, 10% of the acromegaly patients show
no changes in GH levels upon the SA treatment (10).
The genetic basis of acromegaly and drug resistance
remains largely unclear (reviewed in (11)). It has been
shown that somatic mutations in the Gsa gene (GNAS)
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cyclase and that these mutations are found in roughly
40% of somatotropinomas resulting in increased
sensitivity to the inhibitory action of somatostatin
(12). Very few germline mutations are known that are
implicated in inherited pituitary tumor risk. Recently, it
was shown that pituitary adenoma predisposition in
familial cases are due to mutations in the aryl
hydrocarbon receptor-interacting protein (AIP) gene
(13) and may also play a role in aggressive disease
development in sporadic cases of somatotropinomas
(14, 15). As far as the acromegaly and SSTRs are
concerned, only a few genetic association studies have
been conducted. Filopanti et al. (16) identiﬁed that the
rs3751830 and rs169068 alleles are weakly associated
with altered GH and IGF1 levels in patients with
acromegaly. To date, the only non-synonymous SSTR
mutation that may be associated with drug resistance in
acromegaly treatment is a germline R240W mutation
in the SSTR5 that was found in one patient resistant to
octreotide (17). Since almost no genetic mutations of
SSTR2 and SSTR5 have been found in resistant patients
(18, 19), the resistance has been attributed to impaired
SSTR2 and SSTR5 expression in tumor tissues (10, 20).
In this study, we performed sequencing of the SSTR5
gene in 144 subjects and investigated potential corre-
lations between SSTR5 gene variants and disease
outcome as well as the clinical and hormonal charac-
teristics in 48 acromegaly patients and 475 controls.
Materials and methods
Study group
We followed the STREGA guidelines (21) to describe the
study group selection and association analysis. Case–
control study groups were selected from the Latvian
Genome Database (LGDB), a government funded
biobank. All participants of LGDB were over 18-years
of age, and information about their health status was
afﬁrmed by physicians using International Classiﬁcation
of Diseases (ICD)-10 codes. Anthropometric measure-
ments (including weight and stature) were obtained
by direct measurement; ethnic, social, environmental
information, and familial health status were obtained
using a questionnaire-based interview. Participants
of the LGDB were recruited by medical personnel
in hospitals or general practices. Recruitment was
population based (a speciﬁc health condition was not
the obligatory requirement for involvement). Signed
consent forms were acquired from all participants. The
Biobank protocol was approved by the Central Medical
Ethics Committee of Latvia (protocols no. A-30, 2005
and A-7, 2007).
Forty-eight acromegaly patients recruited for this
study were enrolled on to the LGDB between 2004 and
2008 from two main hospitals: Pauls Stradins Clinical
University Hospital (41 patients) and Riga Eastern
Clinical University Hospital (seven patients) represent-
ing w80% of all the acromegaly patients registered in
Latvia as recorded in October 2008 (diagnosed with
acromegaly from 1985 to 2007). Additional data were
collected based on hospital records and interviews for all
the patients selected for the study (ICD-10 code E22.0).
Forty-ﬁve patients received the SA octreotide (Sandos-
tatin LAR) at dose 10–30 mg in every 28 days or
lanreotide (Somatuline Autogel) at dose 60–90 mg in
every 28 days. Tumor size was measured as the
maximum diameter obtained from magnetic resonance
imaging data and tumors were classiﬁed accordingly
as microadenomas (!10 mm) or macroadenomas
(R10 mm). The effect of SA on tumor proliferation
and IGF1 level normalization was estimated by
comparing the tumor sizes and serum IGF1 (mg/ml)
measurements during the course of therapy. To estimate
the dynamics of adenoma size, the data from last follow-
up was compared with the ﬁrst available measurement
with at least a 12-month period in between. We
excluded all cases where the therapy was interrupted
or adenoma resections were performed during this
period. Two groups were deﬁned: ‘reduced’ with
observable tumor shrinkage (nZ11) and ‘unchanged’
with no observable tumor shrinkage (nZ22) together
with the cases that showed prolonged expansion (nZ2).
Only a limited number of cases had IGF1 measurements
available before the therapy. For the IGF1 response,
only the data at least 6 months after the start of the SA
therapy were considered for analysis and only if the
therapy was not interrupted. In those cases where
several IGF1 measurements were available, the mean
IGF1 was calculated, excluding the outliers where
possible. Non-responsiveness was deﬁned as the mean
IFG1 value above the upper limit of normal (ULN) value
at the corresponding age. Owing to the lack of
uniformity in the GH measurements, we did not include
the GH levels in this analysis.
As controls (control I), 96 samples were randomly
chosen for sequencing from LGDB participants excluding
patients with metabolic and endocrine diseases. To
minimize the risk of false positivity, we selected an
additional control group (control II) who were sex- and
age-matched consistingof475 LGDBparticipants.Asper
the selection criteria, we used 63 participants from the
control I who were also included in the control II group.
Detailed sample selection procedure is described in
Supplementary Material, see section on supplementary
data given at the end of this article. Study protocol was
approved by Central Medical Ethics Committee of Latvia
(protocols no. A-33, 2005 and A-3, 2008).
DNA analysis
DNA samples were provided by LGDB and aliquoted into
96-well PCR plates or PCR tubes by Tecan Freedom Evo
robotic pipette. The ﬁnal DNA amount was 28 ng/well.
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including 50 and entire coding region (from K2239 to
C1294 respective to start codon) were ampliﬁed in six
PCR reactions and sequenced using BigDye chemistry
and ABI Prism 3100 (AME Bioscience, Toroed, Norway)
capillary electrophoresis sequencer. All chromatograms
were manually inspected using Contig Express Software
of Vector NTI Advance 9.0 package (Invitrogen).
Presence of polymorphisms was conﬁrmed by opposite
strand analysis. Genotyping was carried out using
minisequencing and subsequent MALDI-TOF mass
spectrometry analysis. Primers were designed on
Primer3 Software (source code available at http://fokker.
wi.mit.edu/primer3/) and using the program CalcDalton
(www.uni-leipzig.de/wahnert/calcdalton.htm). Detailed
experimental procedures can be found in Supplementary
Material and primer sequences can be found in
Supplementary Table 1, see section on supplementary
data given at the end of this article.
Statistical analysis
StatisticalanalysiswasperformedbythePLINK1.07(22)
and SPSS (standard version 13; SPSS, Chicago, IL, USA)
software. Deviation from Hardy–Weinberg equilibrium
was assessed by the exact test described by Wigginton
et al. (23) which is considered more accurate for rare
genotypes. The Cochran–Armitage trend test was used
for association analysis in the case–control group and
Bonferronicorrectionwasapplied.Haplotypeassociation
was performed as implemented in PLINK. For the
quantitative analyses, the IGF1 data were transformed
as a normalized percentage of ULN of appropriate age
according to formula (CIGF1KULNIGF1)/ULNIGF1!100).
Normalized IGF and all other continuous variables
displayed normal distribution and were further used in
linear regression analysis. Two-sided Fisher exact test
was used to test the allelic distribution in the case of
categorical clinical variables, except the analysis of
number of adenoma resections where Pearson c
2 was
calculated from 3!3 table. Permutation tests with
100 000 permutations were performed for each analysis
and we usedcorrected(EMP2) P values. These values are
corrected based on calculation of the proportion of
permutations in which any of the test statistics exceeds
the particular observed statistic and are more stringent
than uncorrected P values.
Results
DNA samples of all 48 available acromegaly patients
and 96 control individuals were subjected to direct
sequencing of the SSTR5 gene including both the
coding and the ﬂanking regions (K2239 to 1294
respective to start codon). Baseline demographic and
clinical characteristics are given in Table 1. In total, 19
polymorphisms were identiﬁed (relative positions,
sequencing success rate and Hardy–Weinberg test
results are shown in Supplementary Table 2, see section
on supplementary data given at the end of this article).
All single nucleotide polymorphisms (SNPs) were in
Hardy–Weinberg equilibrium. Fourteen SNPs passed
the quality and minimal minor allele frequency (MAF)
criteria and were included in the subsequent analysis.
Three SNPs were excluded due to low sequencing
success rate (!95%) and two SNPs were excluded due
to low MAF (!0.01).
The minor alleles of three SNPs were independently
associated with the presence of acromegaly (Table 2)
using Cochran–Armitage trend test. T and A alleles of
rs34037914 and rs642249, respectively, remained
associated with acromegaly after adjusting for multiple
comparisons using both Bonferroni correction and
adjusted permutation test. The ﬁrst control group
(control I) contained some individuals with malignant
and benign neoplasms (23%). To avoid the inﬂuence of
age, gender, or medical conditions on the association
results, as well as to minimize type I error, we selected
an additional age- and gender-matched control group
representing 475 healthy individuals. Genotypingof the
three SNPs (rs34037914, rs169068, and rs642249)
associated with acromegaly was performed in this study
group. Genotyping results for these individuals corre-
sponded to the genotypes previously obtained from the
Table 1 Characteristics ofthe studypopulation.Data arepresented
as mean (S.D.) or n (%).
Variables
Acromegaly
patients
(nZ48)
Control I
(nZ96)
Control II
(nZ475)
Sex
Female 32 (67%) 67 (70%) 324 (68%)
Male 16 (33%) 29 (30%) 151 (32%)
Age (years) 55.8 (12.8) 53.2 (17.4) 54.3 (13.4)
BMI (kg/m
2) 29.9 (5.5) 25.4 (4.4) 27.6 (5.2)
Waist (cm) 91.0 (13.7) – –
Age at diagnosis (years) 47.4 (13.1) – –
Tumour size
Macroadenoma 31 (64%) – –
Microadenoma 17 (36%)
Effect of SA on tumor size (nZ35)
Reduced 11 (31.5%) – –
Unchanged 24 (68.5%)
Expanded
Adenoma resections per patient
1 23 (47.9%) – –
2 2 (4.1%)
3 2 (4.1%)
IGF1 norm
% ULN before treatment (nZ20) 178.8 (87.9) – –
% ULN after treatment (nZ39) 50.8 (77.8)
IGF1 responsiveness (nZ39)
!ULN 12 (30%)
OULN 27 (70%)
BMI, body mass index; IGF1, insulin-like growth factor 1; ULN, upper limit of
normal at corresponding age group; IGF1 norm, % ULN, normalized
percentage of ULN ((CIGF1KULNIGF1)/ULNIGF1!100)).
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associated with the presence of acromegaly (Table 2).
Six haplotypes were derived from the three candidate
SNPs in acromegaly patients and control II group
(Table 3). Four haplotypes (frequency O1% in control
group) were subjected to the haplotype-based associ-
ation analysis. The overall joint test of the SSTR5
haplotypes on presence of acromegaly (comparing
acromegaly patients and control II group) was highly
signiﬁcant (PZ3.4!10
K6). For haplotype-speciﬁc tests
the most common haplotype (56%) that contains only
the common alleles of the three included SNPs (C-T-G)
was chosen as a reference haplotype (Hap1). Hap3
(C-C-A) and Hap4 (T-C-G) contained the independently
associated alleles of rs642249 and rs34037914,
respectively, and were found with signiﬁcantly higher
frequency in acromegaly patients than in controls. Both
these haplotypes also contain the C allele of rs169068
that was independently associated with acromegaly.
On the contrary, Hap2 (C-C-G), which in addition to
common rs642249 and rs34037914 alleles contains
the rs169068 C allele, was not associated with
acromegaly indicating that the association of this allele
with the acromegaly is due to linkage disequilibrium
(LD) with the minor alleles of both other SNPs.
We also tested the association of rs642249 and
rs34037914 with different disease characteristics and
phenotypes affected by acromegaly (Tables 4 and 5).
The following categorical variables in the group of
acromegaly patients were tested: size of adenoma
(microadenoma versus macroadenoma), change in the
size of adenoma as a result of use of medication (reduced
versus unchanged and increased); number of adenoma
resections per patient (0 vs 1 vs 2–3); and IGF1 levels
Table 2 Single nucleotide polymorphism (SNP) association analysis in acromegaly patients and controls.
SNP codes
Alleles/
position
a AA change MAF case
MAF
controls
Allelic OR
(95% CI) P trend
b P perm
c
Acromegaly patients (nZ48) versus control I sample (nZ96)
rs550713 T-2190G 0.078 0.036 2.23 (0.76–6.56) 0.16 0.84
NA T-2138delT 0.427 0.479 0.81 (0.49–1.34) 0.43 1
rs535338 A-1670G 0.202 0.266 0.7 (0.38–1.27) 0.24 0.97
NA C-805G 0.043 0.044 0.97 (0.28–3.3) 0.96 1
rs4988479 G27A 0.021 0.031 0.67 (0.13–3.4) 0.63 1
rs4988483 C142A P335L 0.021 0.016 1.34 (0.22–8.16) 0.75 1
rs4988484 C155T A52V 0.021 0.042 0.49 (0.1–2.35) 0.40 1
rs4988487 C325T P109S 0.021 0.042 0.49 (0.1–2.35) 0.40 1
rs35072648 G516A 0.031 0.047 0.66 (0.17–2.48) 0.56 1
rs34947461 G573A 0.021 0.031 0.66 (0.13–3.33) 0.65 1
rs34037914 C633T 0.146 0.036 4.51 (1.76–11.6) 0.0015* 0.019
NA G693A 0.021 0.016 1.34 (0.22–8.16) 0.75 1
rs169068 T1004C P335L 0.594 0.429 1.94 (1.18–3.21) 0.013 0.11
rs642249 G1044A 0.208 0.073 3.35 (1.61–6.97) 0.0016* 0.020
Acromegaly patients (nZ48) versus Control II sample (nZ475)
rs34037914 C633T 0.146 0.048 3.38 (1.78–6.42) 0.00016* 0.0012
rs169068 T1004C P335L 0.594 0.434 1.91 (1.25–2.93) 0.0029 0.0089
rs642249 G1044A 0.208 0.098 2.41 (1.41–4.13) 0.0014* 0.0064
AA, amino acid; MAF, minor allele frequency; OR, odds ratio; CI, conﬁdence interval; NA, not acquired; association results for SNPs with P!0.05 are marked
with bold. *Signiﬁcant after Bonferroni correction (signiﬁcances level 0.0029).
aNucleotide position relative to the SSTR5 start codons, major allele is shown before and minor allele after the number indicating the nucleotide position.
bP value from Cochran–Armitage trend test.
cP value obtained from 100 000 permutation and corrected for multiple testing (EMP2).
Table 3 Haplotype based association in acromegaly patients and control II sample.
Haplotype frequency (number)
Names Haplotypes
a Cases Control II OR (95% CI) P values
b
Hap1 C-T-G 0.385 (37) 0.562 (534) Ref Ref
Hap2 C-C-G 0.260 (25) 0.293 (279) 1.3 (0.76–2.2) 0.3358
Hap3 C-C-A 0.188 (18) 0.096 (91) 2.85 (1.56–5.22) 0.0016
Hap4 T-C-G 0.146 (14) 0.045 (43) 4.69 (2.35–9.34) 0.000053
Hap5 C-T-A 0.021 (2) 0.002 (2) NC NC
Hap6 T-T-G 0 (0) 0.001 (1) NC NC
OR, odds ratio; CI, conﬁdence interval; Ref, reference group; NC, not calculated; association results for haplotypes with P!0.05 are
marked with bold.
aSNP orderZrs34037914 – rs169068 – rs642249.
bP value from Fisher exact test.
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mass index (BMI), age at acromegaly diagnosis and age-
adjusted normalized IGF1 levels were used as continu-
ous variables in the linear regression analysis (Table 5).
rs642249 had no association with any of these
phenotypes. However, rs34037914 was signiﬁcantly
associated with the number of these phenotypes
(summarized in Supplementary Figure 1, see section
on supplementary data given at the end of this article).
Carriers of the rs34037914 T allele were characterized
by signiﬁcantly lower mean age at diagnosis (P valueZ
0.002) and increased BMI value (P valueZ0.004).
Association of the T allele with these variables
correspondedbesttotheadditivegeneticmodel(Tables4
and 5, Supplementary Figure 1, see section on
supplementary data given at the end of this article).
No association (PZ0.56) was observed between
rs34037914 and increased waist circumference (this
measurement was only available for 23 patients)
indicating that association of rs34037914 with
increased BMI in this group is due to an increase in
muscle and bone mass caused by acromegaly rather
than to an increase in fat mass. In addition, we tested
whether the rs34037914 allele is associated with BMI
and stature in the healthy individuals, but we found
no differences between the genotype groups (data not
shown) for any of the genetic models. Interestingly, the
rs34037914 risk (T) allele was absent in the group of
patients with observable tumor shrinkage as a result of
octreotide or lanreotide treatment, resulting in associ-
ation between this parameter and presence of the
rs34037914 T allele (P valueZ0.014). Even more
intriguing, the presence of the same allele was positively
correlated with the number of adenoma resections per
patient (P valueZ0.0001). Among the four patients
in the entire study group who had more than one
adenoma resection, two were homozygotes for the
rs34037914 T allele and one was a carrier of the same
allele in the heterozygous state. We also observed an
increased rs34037914 Tallele frequency in patients who
failed to normalize their IGF1 levels compared with those
who reached normal IGF1 levels after the SA treatment.
Similarly,themeannormalizedIGF1levelswereincreased
in patients with rs34037914 CTand TT genotypes in an
additive manner (Table 5). None of these differences,
however, reached a statistical signiﬁcance.
Table 4 Categorical analysis of SNP association with different phenotypes in acromegaly patients.
Phenotype
Genotype
distribution MAF
Allelic OR
(0.95% CI) P value
a P perm
b
SNP: rs34037914
TT/TC/CC
Size of adenoma 1.44 (0.42–5.00) 0.56 0.62
Micro 0/4/13 0.11
Macro 2/6/23 0.16
Effect of SA on tumor size NA 0.014 0.02
Reduced 0/0/11 0
Enlarged 2/7/15 0.22
IGF1 after treatment 3.27 (0.64–16.54) 0.13 0.17
Below ULN 0/2/11 0.07
Above ULN 2/5/14 0.21
Number of adenoma resections NC NA 0.0001
c NC
0 0/4/16
1 0/5/18
2–3 2/1/1
SNP: rs642249
AA/AG/GG
Size of adenoma 1.03 (0.28–3.82) 0.63 0.68
Micro 2/4/11 0.19
Macro 2/8/21 0.24
Effect of SA on tumor size 0.78 (0.28–2.15) 0.96 0.96
Reduced 1/2/8 0.19
Enlarged 2/5/17 0.18
IGF1 after treatment 1.04 (0.33–3.31) 0.94 0.95
Below ULN 2/2/9
Above ULN 1/8/12 0.24
Number of adenoma resections NC NC 0.5
c NC
0 2/6/12
1 2/6/15
2–3 0/0/4
OR, odds ratio; CI, conﬁdence interval; MAF, minor allele frequency; NA, not applicable; NC, not calculated. Association results with
P!0.05 are marked in bold.
aP value from Fisher exact test.
bP value obtained from 100 000 permutation.
cP value from Pearson c
2 calculation using 3!3 table (4 degrees of freedom).
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In this study, we present a novel and highly signiﬁcant
association of two SNPs, rs34037914 and rs642249,
in the SSTR5 gene with acromegaly. This association
remains signiﬁcant after both Bonferroni correction and
adjusted permutation tests. Both SSTR2 and SSTR5
are potential candidate genes for an increased risk to
develop acromegaly and poor response to SA, due to
their important role in controlling GH secretion and
somatotroph growth. However, until now there has
been a lack of convincing association between genetic
variants of any of the SSTRs and acromegaly or
resistance to the action of somatostatin or SA (reviewed
in (11)). This can be explained in part by the
observation that rare SNPs are often not included in
genotyping due to low power in studies with a limited
number of patients. Thus, to avoid a selection bias, an
important issue in genetic studies of rare disease, we
performed sequencingof the SSTR5 gene in all available
patients and substantial number of controls. We
identiﬁed four novel polymorphisms (one single nucleo-
tide deletion and three SNPs) that were not previously
reported to the SNP databases among the total of 19
polymorphisms (Supplementary Table 2, see section on
supplementary data given at the end of this article). The
allele frequencies of the previously known SNPs showed
a variable prevalence, which was comparable to the
allele frequencies reported in databases or previously
published reports (http://www.genecards.org/cgi-bin/
carddisp.pl?geneZSSTR5&snpZ207&searchZsstr%
205&rfZ/home/genecards/current/website/carddisp.
pl#snp). The prevalence of three SNPs was signiﬁcantly
different in acromegaly patients compared individually
with a sex- and age-matched control group. Our
haplotype analysis suggests that the non-synonymous
polymorphism rs169068 (Pro335Leu) is not associated
with acromegaly. The difference in allele frequencies
between cases and controls for this SNP can be
explained by strong LD between rs169068 C allele
(Pro) and both associated alleles of rs642249 and
rs34037914. Interestingly, the C allele of rs169068 has
been previously associated with decreased IGF1 (16) in
acromegaly patients. Our results may rather suggest an
opposite effect due to LD between the C allele and
rs34037914 T allele, as the latter has a non-signiﬁcant
tendency toward increased IGF1 levels. Unfortunately,
the rs34037914 and rs642249 were not genotyped in
a study performed Filopantyet al. (16) The C allele of the
rs169068 was associated with the presence of bipolar
affective disorder in a British but not in a Danish
population (24), while there was a lack of association
with autism in both Danish and French populations
(25). No association was found between this SNP and
risk or survival of pancreatic cancer (26). To our best
knowledge, the rs34037914 and rs642249 have not
been tested previously with respect to acromegaly. The
presence of the A allele of rs642249 was associated
with increased mean IGF1 levels, but not with risk of
breast cancer in the international EPIC study (27).
Neither rs34037914 nor rs642249 has shown associ-
ations with bipolar affective disorder (24).
The importance of the four SNPs from the SSTR5
gene locus on regulation of IGF1 levels has recently
been demonstrated in a large multinational study on
samples from the Breast and Prostate Cancer Cohort
Consortium (28). One of these SNPs, the rs3751830,
was also found in our study, but was not included in
the ﬁnal analysis due to low genotype call rate
(Supplementary Table 2, see section on supplementary
data given at the end of this article). However, no
signiﬁcant differences were found between the allele
frequencies of this SNP and any of the phenotypes
studied (data not shown). Data on LD between
associated SNPs rs34037914 or rs642249 and other
SNPs from the above mentioned study are not available
and it is difﬁcult to assess if these SNP may be part of the
same haplotype or if they could represent functional
SNPs. It is also clear that physiological consequences of
the same genetic SSTR5 variants may be very different
when a normal pituitary gland is considered compared
with pituitary tumors. Unfortunately, the IGF1 levels for
the control group were not available in our study, and
this would help to assess the effects of these SNPs in on
IGF1 regulation in healthy individuals.
rs34037914 shows the strongest association
with acromegaly (odds ratioZ3.38, 95% conﬁdence
intervalZ1.78–6.42) assuming an additive mode of
inheritance. We strongly suggest that this is not a false-
positive ﬁnding since the same rs34037914 allele is
associated with a number of independent clinical
characteristics in our group of acromegaly patients.
This is the ﬁrst study that reports such a pronounced
effect of genetic variants on body mass in the case of
Table 5 Qualitative analysis of SNP association with different
phenotypes in acromegaly patients.
Phenotypes (meanGS.E.M.)
Genotype BMI (kg/m
2)
Age at
diagnosis (y) IGF1 % ULN
SNP: rs34037914
CC 28.87G0.80 50.43G2.03 45.40G14.61
CT 31.35G2.00 40.60G3.90 63.23G30.03
TT 40.48G1.03 28.50G7.50 80.23G32.28
P value
a 0.004 0.002 0.41
P perm
b 0.012 0.006 0.81
SNP: rs642249
GG 31.04G1.06 27.19G1.29 28.33G0.98
GA 48.25G2.33 46.00G3.68 44.50G8.85
AA 40.72G16.08 88.52G19.92 19.93G23.53
P value
a 0.09 0.51 0.23
P perm
b 0.23 0.87 0.97
IGF1 % ULN, normalized percentage of ULN ((CIGF1KULNIGF1)/ULNIGF1!
100). Association results with P!0.05 are marked in bold.
aP value from linear regression.
bP value obtained from 100 000 permutation.
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larger in the T allele homozygotes compared with wild-
type (wt) homozygotes. Similarly, the median age at
diagnosis was 22 years earlier considering the same
group of patients. This is in line with previous data
obtained in a large international collaborative study
showing earlier onset age when investigating germ line
mutations in the AIP (15) a gene that initially was
associated with familial pituitary adenoma cases (13).
According to our data, the T allele of rs34037914
predisposes to increased aggressiveness and post-
surgical reoccurrence of pituitary tumors as well as
non-responsiveness to antiproliferative effects of SA. The
increased BMI in carriers of the T allele, however,
indicates that the effect of this polymorphism is not
limited to the regulation of tumor cell proliferation, but
also affects the systemic GH levels. We did not observe
the same effects of rs642249, the other acromegaly
associated SNP, on the clinical or hormonal charac-
teristics in our patient group. If not false positive, this
may be explained by the smaller effect size of this SNP
and a larger cohort of acromegaly patients would be
needed to provide conclusive results. Alternatively, the
disease predisposing effect linked to rs642249 may not
be associated with characteristics available in our study.
It is not clear how the synonymous rs34037914 is
connected with functional effects. First, other functional
mutations in LD with rs34037914 may exist outside
the regions we sequenced. It is plausible that such
mutations, or rs34037914, are inﬂuencing the
expression of SSTR5. Although the unresponsiveness
to SA has been clearly associated with low expression of
SSTR2 (29–31), the SSTR5 is the most abundantly
expressed receptor in somatotropinomas (18, 32, 33)
and it plays an important role in mediating the effect of
somatostatin. The relative contribution of each of those
receptors in the control of GH secretion is still unclear.
It is established that both receptors are needed for
hormonal regulation since the activation of SSTR2 and
SSTR5 results in a synergistic effect on GH release (34–
36). Thus, if the rs34037914 or rs642249 is linked to
the changes in SSTR5 expression, they may signi-
ﬁcantly inﬂuence the responsiveness of the pituitary
tumor cells to somatostatin and its analogs. Genotyping
the rs34037914 and rs642249 in patients with known
SSTR5 and SSTR2 expression proﬁles from pituitary
tumors would help to test this hypothesis. Another
possibility is that the particular sequence variations
may induce alternative/de novo splicing creating a non-
functional receptor protein or receptor with altered
functions. It has indeed been shown that SSTR5 is found
in two isoforms in pituitary tumors and that these
are presumably generated by a splicing of the SSTR5
involving the presence of a cryptic donor and acceptor
splice site (37). One of these variants, named
SST5TMD4, has been found to be abundantly present
in octreotide-resistant somatotropinomas and could
interfere with the normal inhibitory response of
adenomas to somatostatin (38). rs34037914 is actually
located close to the splice site of the other variant
SST5TMD5, and it is possible that this polymorphism
may be important for this donor splice site formation.
Functional consequences of the truncated receptor
protein could involve its ability to interact with
SSTR5 or SSTR2 leading to non-functional hetero-
dimers. It has been shown previously that SSTR5 can
form heterodimers with different GPCRs (reviewed in
(39)), including SSTR2 and dopamine D2 receptors
heterodimers with enhanced functionality (40, 41).
It is unlikely that changes in the amino acid sequence
are responsible for the effects found in our study
considering the functional importance of these SNPs.
The non-synonymous substitution rs169068 is located
in the C-terminal intracellular tail of the receptor
causing a proline to leucine change. It has been
shown by mutational analysis that the C-terminal
domain is involved in the interaction with adenylate
cyclase and is important for desensitization and
internalization of this receptor (42). A recent study
has shown that SSTR5 with leucine at position 335
loses its inhibitory effect on cell proliferation compared
with the proline variant (43). However, It is unlikely
that this substitution has a major impact on tumor
development or drug resistance in our study group, as
the proline was actually more frequent among the
acromegaly patients (59.4% C allele frequency) while a
majority of the general population carry SSTR5 with
leucine in this position (56.6% T allele frequency).
According to the SNP NCBI database and the HapMap
data on European, African, and Asiatic populations
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.
cgi?rsZ169068), the distribution of this variant differs
signiﬁcantly among the ethnic groups. The frequency
of the T allele, as far as the HapMap data is considered,
varies from 27% in the African American population
and 52% in the Caucasian population to 85% in the
Japanese and Chinese populations.
The major limitation of this study is the lack of
standardized GH and IGF1 measurements for all
acromegaly patients that did not allow a full estimation
of the inﬂuence of these polymorphisms on hormonal
regulation and drug responsiveness. Similarly, it was
not possible to test the eventual effect of polymorphisms
on the level of SSTR5 expression due to the unavail-
ability of the tumor tissue samples. Replication studies
with a larger patient size and other ethnic groups would
provide additional insight into the associations that we
have identiﬁed.
In conclusion, we have identiﬁed genetic variations
in SSTR5 that are strongly associated with acromegaly
and several of the clinical characteristics related to this
disease. If tested functionally and proven clinically
rs34037914 has a potential to become a diagnostic
marker of non-invasive tests to determine the prognosis
and aggressiveness of somatotropinomas.
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